Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors

Phase 1

Terminated

Conditions: Colorectal Adenocarcinoma
Metastatic Gastric Carcinoma
Metastatic Cholangiocarcinoma
Metastatic Esophageal Carcinoma
Metastatic Pancreatic Adenocarcinoma
Stage IV Gastric Cancer AJCC v7
Stage IV Pancreatic Cancer AJCC v6 and v7
Stage IV Esophageal Cancer AJCC v7
Stage IVA Colorectal Cancer AJCC v7
Metastatic Colorectal Carcinoma

Interventions: Biological: Adoptive Immunotherapy
Biological: Aldesleukin
Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab

First Posted Date: 2016-05-02

Last Posted Date: 2020-10-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT02757391

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia

Phase 2

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Recurrent Chronic Lymphocytic Leukemia
Recurrent Small Lymphocytic Lymphoma
Refractory Chronic Lymphocytic Leukemia
Refractory Small Lymphocytic Lymphoma

Interventions: Drug: Ibrutinib
Other: Laboratory Biomarker Analysis
Drug: Venetoclax

First Posted Date: 2016-04-29

Last Posted Date: 2025-01-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 234

Registration Number: NCT02756897

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery

Phase 1

Completed

Conditions: Stage IV Colorectal Cancer AJCC v7
Resectable Mass
Stage IVA Colorectal Cancer AJCC v7
Stage IVB Colorectal Cancer AJCC v7
Metastatic Carcinoma in the Liver

Interventions: Biological: Durvalumab
Other: Laboratory Biomarker Analysis
Procedure: Therapeutic Conventional Surgery
Biological: Tremelimumab

First Posted Date: 2016-04-28

Last Posted Date: 2024-10-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT02754856

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment

Phase 2

Active, not recruiting

Conditions: Stage I Breast Cancer AJCC v7
Stage IA Breast Cancer AJCC v7
Stage IB Breast Cancer AJCC v7
Stage II Breast Cancer AJCC v6 and v7
Stage IIA Breast Cancer AJCC v6 and v7
Stage IIB Breast Cancer AJCC v6 and v7
Stage III Breast Cancer AJCC v7
Stage IIIA Breast Cancer AJCC v7
Stage IIIB Breast Cancer AJCC v7
Stage IIIC Breast Cancer AJCC v7

Interventions: Procedure: Electroacupuncture Therapy
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2016-04-28

Last Posted Date: 2025-04-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 111

Registration Number: NCT02754752

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

Not Applicable

Recruiting

Conditions: Recurrent Brain Neoplasm
Brain Neoplasm
Metastatic Malignant Neoplasm in the Brain

Interventions: Procedure: Direct Electrocortical Stimulation
Other: Electrocorticography

First Posted Date: 2016-04-28

Last Posted Date: 2025-05-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 75

Registration Number: NCT02754544

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Non-Surgical Management of Attenuated and Deleterious (Classical) Familial Adenomatous Polyposis: A Long-term Surveillance Program

Completed

Conditions: Deleterious Familial Adenomatous Polyposis
Attenuated Familial Adenomatous Polyposis

Interventions: Other: Chart Review

First Posted Date: 2016-04-22

Last Posted Date: 2022-09-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1500

Registration Number: NCT02747862

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer

Early Phase 1

Active, not recruiting

Conditions: Estrogen Receptor Negative
Progesterone Receptor Negative
HER2/Neu Negative
Triple-Negative Breast Carcinoma

Interventions: Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Other: Laboratory Biomarker Analysis
Radiation: Scintimammography
Drug: Technetium Tc-99m Sestamibi

First Posted Date: 2016-04-20

Last Posted Date: 2025-04-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 96

Registration Number: NCT02744053

Locations: 🇺🇸
MD Anderson in Katy, Houston, Texas, United States
🇺🇸
MD Anderson League City, Nassau Bay, Texas, United States
🇺🇸
Memorial Hermann Memorial City Medical Center, Houston, Texas, United States

and more 3 locations

Evaluate Use of Caudal Nerve Blocks in Adult Penile Prosthesis

Phase 3

Completed

Conditions: Malignant Neoplasms of Male Genital Organs

Interventions: Procedure: Caudal Nerve Block (CNB)
Drug: Ropivacaine
Drug: Epinephrine
Drug: Decadron
Drug: Clonidine
Drug: Propofol
Behavioral: Phone Call

First Posted Date: 2016-04-15

Last Posted Date: 2022-01-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 52

Registration Number: NCT02740127

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway

Phase 3

Terminated

Conditions: Malignant Neoplasms of Female Genital Organs
Gynecologic Cancer

Interventions: Drug: Bupivacaine
Drug: Liposomal Bupivacaine
Drug: Oxycodone
Behavioral: Symptom Questionnaire
Behavioral: Pill Diary

First Posted Date: 2016-04-15

Last Posted Date: 2021-10-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 105

Registration Number: NCT02740114

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery

Phase 2

Active, not recruiting

Conditions: Recurrent Colorectal Carcinoma
Metastatic Colorectal Carcinoma
Metastatic Malignant Neoplasm in the Lung
Stage IVA Colorectal Cancer AJCC v7
Stage IVB Colorectal Cancer AJCC v7
Metastatic Malignant Neoplasm in the Liver
Resectable Colorectal Carcinoma
Stage IV Colorectal Cancer AJCC v7

Interventions: Drug: Chemotherapy
Other: Laboratory Biomarker Analysis
Procedure: Metastasectomy
Other: Quality-of-Life Assessment
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2016-04-14

Last Posted Date: 2025-02-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 29

Registration Number: NCT02738606

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy